The poxvirus A35 protein is an immunoregulator

Journal of Virology

Volumn 84, Issue 1, 2010, Pages 418-425

  Rehm, Kristina E ^a   Jones, Gwendolyn J B ^a   Tripp, Alice A ^a   Metcalf, Mark W ^a   Roper, Rachel L ^a  

^a EAST CAROLINA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

A35 PROTEIN; GAMMA INTERFERON; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CELL SECRETION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DELETION MUTANT; FEMALE; GENE DELETION; GENE REPLICATION; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOREGULATION; LETHAL DOSE; MOUSE; NONHUMAN; POXVIRUS; PRIORITY JOURNAL; VIRUS MUTANT; VIRUS TITRATION; VIRUS VIRULENCE; WILD TYPE;

ANIMALS; ANTIBODIES, NEUTRALIZING; GENE DELETION; IMMUNOLOGIC FACTORS; MICE; MICE, INBRED BALB C; POXVIRIDAE; VACCINES, ATTENUATED; VACCINIA; VACCINIA VIRUS; VIRAL PROTEINS; VIRAL VACCINES; VIRULENCE FACTORS;

MUS; POXVIRIDAE; VACCINIA VIRUS;

EID: 72849122956     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.01802-09     Document Type: Article

References (49)

1. Bell, E., M. Shamim, J. C. Whitbeck, G. Sfyroera, J. D. Lambris, and S. N. Isaacs. 2004. Antibodies against the extracellular enveloped virus B5R protein are mainly responsible for the EEV neutralizing capacity of vaccinia immune globulin. Virology 325:425-431. (Pubitemid 38902805)
2. Belyakov, I. M., P. Earl, A. Dzutsev, V. A. Kuznetsov, M. Lemon, L. S. Wyatt, J. T. Snyder, J. D. Ahlers, G. Franchini, B. Moss, and J. A. Berzofsky. 2003. Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses. Proc. Natl. Acad. Sci. U. S. A. 100:9458-9463.
3. Brandt, T. A., and B. L. Jacobs. 2001. Both carboxy- and amino-terminal domains of the vaccinia virus interferon resistance gene, E3L, are required for pathogenesis in a mouse model. J. Virol. 75:850-856.
4. Calvo-Calle, J. M., I. Strug, M. D. Nastke, S. P. Baker, and L. J. Stern. 2007. Human CD4+ T cell epitopes from vaccinia virus induced by vaccination or infection. PLoS Pathog. 3:1511-1529.
5. Chaudhri, G., V. Panchanathan, H. Bluethmann, and G. Karupiah. 2006. Obligatory requirement for antibody in recovery from a primary poxvirus infection. J. Virol. 80:6339-6344. (Pubitemid 43927437)
6. Chen, N., G. Li, M. K. Liszewski, J. P. Atkinson, P. B. Jahrling, Z. Feng, J. Schriewer, C. Buck, C. Wang, E. J. Lefkowitz, J. J. Esposito, T. Harms, I. K. Damon, R. L. Roper, C. Upton, and R. M. Buller. 2005. Virulence differences between monkeypox virus isolates from West Africa and the Congo basin. Virology 340:46-63. (Pubitemid 41191177)
7. Clark, R. H., J. C. Kenyon, N. W. Bartlett, D. C. Tscharke, and G. L. Smith. 2006. Deletion of gene A41L enhances vaccinia virus immunogenicity and vaccine efficacy. J. Gen. Virol. 87:29-38.
8. Cosma, A., R. Nagaraj, C. Staib, C. Diemer, F. Wopfner, H. Schatzl, D. H. Busch, G. Sutter, F. D. Goebel, and V. Erfle. 2007. Evaluation of modified vaccinia virus Ankara as an alternative vaccine against smallpox in chronically HIV type 1-infected individuals undergoing HAART. AIDS Res. Hum. Retroviruses 23:782-793.
9. Coulibaly, S., P. Bruhl, J. Mayrhofer, K. Schmid, M. Gerencer, and F. G. Falkner. 2005. The nonreplicating smallpox candidate vaccines defective vaccinia Lister (dVV-L) and modified vaccinia Ankara (MVA) elicit robust long-term protection. Virology 341:91-101. (Pubitemid 41356718)
10. Damaso, C. R., J. J. Esposito, R. C. Condit, and N. Moussatche. 2000. An emergent poxvirus from humans and cattle in Rio de Janeiro State: cantagalo virus may derive from Brazilian smallpox vaccine. Virology 277:439-449.
11. Davies, D. H., X. Liang, J. E. Hernandez, A. Randall, S. Hirst, Y. Mu, K. M. Romero, T. T. Nguyen, M. Kalantari-Dehaghi, S. Crotty, P. Baldi, L. P. Villarreal, and P. L. Felgner. 2005. Profiling the humoral immune response to infection by using proteome microarrays: high-throughput vaccine and diagnostic antigen discovery. Proc. Natl. Acad. Sci. U. S. A. 102:547-552.
12. Dhar, A. D., A. E. Werchniak, Y. Li, J. B. Brennick, C. S. Goldsmith, R. Kline, I. Damon, and S. N. Klaus. 2004. Tanapox infection in a college student. N. Engl. J. Med. 350:361-366.
13. Drexler, I., C. Staib, W. Kastenmuller, S. Stevanovic, B. Schmidt, F. A. Lemonnier, H. G. Rammensee, D. H. Busch, H. Bernhard, V. Erfle, and G. Sutter. 2003. Identification of vaccinia virus epitope-specific HLA-A*0201- restricted T cells and comparative analysis of smallpox vaccines. Proc. Natl. Acad. Sci. U. S. A. 100:217-222.
14. Eckart, R. E., S. S. Love, J. E. Atwood, M. K. Arness, D. C. Cassimatis, C. L. Campbell, S. Y. Boyd, J. G. Murphy, D. L. Swerdlow, L. C. Collins, J. R. Riddle, D. N. Tornberg, J. D. Grabenstein, and R. J. Engler. 2004. Incidence and follow-up of inflammatory cardiac complications after smallpox vaccination. J. Am. Coll. Cardiol. 44:201-205.
15. Frey, S. E., R. B. Couch, C. O. Tacket, J. J. Treanor, M. Wolff, F. K. Newman, R. L. Atmar, R. Edelman, C. M. Nolan, and R. B. Belshe. 2002. Clinical responses to undiluted and diluted smallpox vaccine. N. Engl. J. Med. 346:1265-1274.
16. Gherardi, M. M., J. C. Ramirez, and M. Esteban. 2003. IL-12 and IL-18 act in synergy to clear vaccinia virus infection: involvement of innate and adaptive components of the immune system. J. Gen. Virol. 84:1961-1972.
17. Hooper, J. W., E. Thompson, C. Wilhelmsen, M. Zimmerman, M. A. Ichou, S. E. Steffen, C. S. Schmaljohn, A. L. Schmaljohn, and P. B. Jahrling. 2004. Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox. J. Virol. 78:4433-4443.
18. Hutin, Y. J., R. J. Williams, P. Malfait, R. Pebody, V. N. Loparev, S. L. Ropp, M. Rodriguez, J. C. Knight, F. K. Tshioko, A. S. Khan, M. V. Szczeniowski, and J. J. Esposito. 2001. Outbreak of human monkeypox, Democratic Republic of Congo, 1996 to 1997. Emerg. Infect. Dis. 7:434-438.
19. Jing, L., T. M. Chong, C. L. McClurkan, J. Huang, B. T. Story, and D. M. Koelle. 2005. Diversity in the acute CD8 T cell response to vaccinia virus in humans. J. Immunol. 175:7550-7559. (Pubitemid 41713454)
20. Jones-Trower, A., A. Garcia, C. A. Meseda, Y. He, C. Weiss, A. Kumar, J. P. Weir, and M. Merchlinsky. 2005. Identification and preliminary characterization of vaccinia virus (Dryvax) antigens recognized by vaccinia immune globulin. Virology 343:128-140. (Pubitemid 41572239)
21. Kemper, A., M. Davis, and G. Freed. 2002. Expected adverse events in a mass smallpox vaccination campaign. Eff. Clin. Pract. 5(2):84-90.
22. Kennedy, R., and G. A. Poland. 2007. T-cell epitope discovery for variola and vaccinia viruses. Rev. Med. Virol. 17:93-113.
23. Kolhapure, R. M., R. P. Deolankar, C. D. Tupe, C. G. Raut, A. Basu, B. M. Dama, S. D. Pawar, M. V. Joshi, V. S. Padbidri, M. K. Goverdhan, and K. Banerjee. 1997. Investigation of buffalopox outbreaks in Maharashtra State during 1992-1996. Indian J. Med. Res. 106:441-446.
24. Learned, L. A., M. G. Reynolds, D. W. Wassa, Y. Li, V. A. Olson, K. Karem, L. L. Stempora, Z. H. Braden, R. Kline, A. Likos, F. Libama, H. Moudzeo, J. D. Bolanda, P. Tarangonia, P. Boumandoki, P. Formenty, J. M. Harvey, and I. K. Damon. 2005. Extended interhuman transmission of monkeypox in a hospital community in the Republic of the Congo, 2003. Am. J. Trop. Med. Hyg. 73:428-434.
25. Lederman, E. R., M. G. Reynolds, K. Karem, Z. Braden, L. A. Learned-Orozco, D. Wassa-Wassa, O. Moundeli, C. Hughes, J. Harvey, R. Regnery, J. V. Mombouli, and I. K. Damon. 2007. Prevalence of antibodies against orthopoxviruses among residents of Likouala region, Republic of Congo: evidence for monkeypox virus exposure. Am. J. Trop. Med. Hyg. 77:1150-1156.
26. Li, P., N. Wang, D. Zhou, C. S. Yee, C. H. Chang, R. R. Brutkiewicz, and J. S. Blum. 2005. Disruption of MHC class II-restricted antigen presentation by vaccinia virus. J. Immunol. 175:6481-6488. (Pubitemid 41598890)
27. Likos, A. M., S. A. Sammons, V. A. Olson, A. M. Frace, Y. Li, M. Olsen-Rasmussen, W. Davidson, R. Galloway, M. L. Khristova, M. G. Reynolds, H. Zhao, D. S. Carroll, A. Curns, P. Formenty, J. J. Esposito, R. L. Regnery, and I. K. Damon. 2005. A tale of two clades: monkeypox viruses. J. Gen. Virol. 86:2661-2672.
28. Mahalingam, S., I. K. Damon, and B. A. Lidbury. 2004. 25 years since the eradication of smallpox: why poxvirus research is still relevant. Trends Immunol. 25:636-639. (Pubitemid 39457974)
29. Molino, A. C., A. B. Fleischer, Jr., and S. R. Feldman. 2004. Patient demographics and utilization of health care services for molluscum contagiosum. Pediatr. Dermatol. 21:628-632.
30. Moss, B. 2001. Poxviruses, p. 2849-2884. In D. M. Knipe, P. M. Howley, D. E. Griffin, R. A. Lamb, M. A. Martin, B. Roizman, and S. E. Straus (ed.), Fields virology, 4th ed., vol.2. Lippincott Williams & Wilkins, Philadelphia, PA.
31. Mukinda, V. B., G. Mwema, M. Kilundu, D. L. Heymann, A. S. Khan, and J. J. Esposito. 1997. Re-emergence of human monkeypox in Zaire in 1996. Monkeypox Epidemiologic Working Group. Lancet 349:1449-1450. (Pubitemid 27212198)
32. Norbury, C. C., S. Basta, K. B. Donohue, D. C. Tscharke, M. F. Princiotta, P. Berglund, J. Gibbs, J. R. Bennink, and J. W. Yewdell. 2004. CD8+ T cell cross-priming via transfer of proteasome substrates. Science 304:1318-1321.
33. Panchanathan, V., G. Chaudhri, and G. Karupiah. 2006. Protective immunity against secondary poxvirus infection is dependent on antibody but not on CD4 or CD8 T-cell function. J. Virol. 80:6333-6338. (Pubitemid 43927436)
34. Parker, S., A. Nuara, R. M. Buller, and D. A. Schultz. 2007. Human monkeypox: an emerging zoonotic disease. Future Microbiol. 2:17-34. (Pubitemid 46766996)
35. Pasquetto, V., H. H. Bui, R. Giannino, F. Mirza, J. Sidney, C. Oseroff, D. C. Tscharke, K. Irvine, J. R. Bennink, B. Peters, S. Southwood, V. Cerundolo, H. Grey, J. W. Yewdell, and A. Sette. 2005. HLA-A*0201, HLA-A*1101, and HLA-B*0702 transgenic mice recognize numerous poxvirus determinants from a wide variety of viral gene products. J. Immunol. 175:5504-5515. (Pubitemid 41456438)
36. Reading, P. C., and G. L. Smith. 2003. Vaccinia virus interleukin-18-binding protein promotes virulence by reducing gamma interferon production and natural killer and T-cell activity. J. Virol. 77:9960-9968.
37. Reed, L. J., and H. A. Muench. 1938. A simple method of estimating fifty per cent endpoints. Am. J. Hyg. 27:493-497.
38. Rehm, K. E., R. F. Connor, G. J. B. Jones, K. Yimbu, M. D. Mannie, and R. L. Roper. 2009. Vaccinia virus decreases MHC class II antigen presentation, T cell priming, and peptide association with MHC class II. Immunology 128:381-392.
39. Roper, R. L. 2006. Characterization of the vaccinia virus A35R protein and its role in virulence. J. Virol. 80:306-313.
40. See, R. H., A. N. Zakhartchouk, M. Petric, D. J. Lawrence, C. P. Mok, R. J. Hogan, T. Rowe, L. A. Zitzow, K. P. Karunakaran, M. M. Hitt, F. L. Graham, L. Prevec, J. B. Mahony, C. Sharon, T. C. Auperin, J. M. Rini, A. J. Tingle, D. W. Scheifele, D. M. Skowronski, D. M. Patrick, T. G. Voss, L. A. Babiuk, J. Gauldie, R. L. Roper, R. C. Brunham, and B. B. Finlay. 2006. Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus. J. Gen. Virol. 87:641-650.
41. Silva-Fernandes, A. T., C. E. Travassos, J. M. Ferreira, J. S. Abrahao, E. S. Rocha, F. Viana-Ferreira, J. R. dos Santos, C. A. Bonjardim, P. C. Ferreira, and E. G. Kroon. 2009. Natural human infections with vaccinia virus during bovine vaccinia outbreaks. J. Clin. Virol. 44:308-313.
42. Stack, J., I. R. Haga, M. Schroder, N. W. Bartlett, G. Maloney, P. C. Reading, K. A. Fitzgerald, G. L. Smith, and A. G. Bowie. 2005. Vaccinia virus protein A46R targets multiple Toll-like-interleukin-1 receptor adaptors and contributes to virulence. J. Exp. Med. 201:1007-1018.
43. Stich, A., H. Meyer, B. Kohler, and K. Fleischer. 2002. Tanapox: first report in a European traveller and identification by PCR. Trans. R. Soc. Trop. Med. Hyg. 96:178-179.
44. Terajima, M., J. Cruz, G. Raines, E. D. Kilpatrick, J. S. Kennedy, A. L. Rothman, and F. A. Ennis. 2003. Quantitation of CD8+ T cell responses to newly identified HLA-A*0201-restricted T cell epitopes conserved among vaccinia and variola (smallpox) viruses. J. Exp. Med. 197:927-932.
45. Upfal, M. J., and S. Cinti. 2004. Smallpox vaccination and adverse cardiac events. Emerg. Infect. Dis. 10:961-962.
46. Vijaysri, S., G. Jentarra, M. C. Heck, A. A. Mercer, C. J. McInnes, and B. L. Jacobs. 2008. Vaccinia viruses with mutations in the E3L gene as potential replication-competent, attenuated vaccines: intra-nasal vaccination. Vaccine 26:664-676.
47. Wyatt, L. S., P. L. Earl, L. A. Eller, and B. Moss. 2004. Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge. Proc. Natl. Acad. Sci. USA 101:4590-4595.
48. Xiao, Z., J. M. Curtsinger, M. Prlic, S. C. Jameson, and M. F. Mescher. 2007. The CD8 T cell response to vaccinia virus exhibits site-dependent heterogeneity of functional responses. Int. Immunol. 19:733-743.
49. Xu, R., A. J. Johnson, D. Liggitt, and M. J. Bevan. 2004. Cellular and humoral immunity against vaccinia virus infection of mice. J. Immunol. 172:6265-6271. (Pubitemid 38621233)